Under construction – not a live service
Sign in
Taking people in EgyptPhase 2/3

Tests ketone esters added to usual care for children with drug-resistant epilepsy

Tests ketone esters added to usual medicine in children with hard-to-control epilepsy.

Plain-language title generated from the registry record
Registry title: Exogenous Ketone Esters for Drug Resistant Epilepsy

Key facts

Where
Sohag, EgyptSee the site
Phase
Phase 2/3

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 1 and 16 years old?

Source: NCT05670847, who can take part

Where in Egypt

  • Department of Pediatrics at Sohag University HospitalSohag, EgyptTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Sohag University
Trial code
NCT05670847
Record updated
27 November 2024
Original description
This study aims to investigate the efficacy of add-on exogenous ketone esters for treating children with drug-resistant epilepsyRead full original descriptionShow less

Efficacy of Ketone Esters for Children With Drug Resistant Epilepsy

This study aims to investigate the efficacy of add-on exogenous ketone esters for treating children with drug-resistant epilepsy

Inclusion: Drug-resistant epilepsy; Seizure frequency ≥ 7 per week.

Exclusion: Recent propofol therapy; Intake of carbonic-anhydrase inhibitors; Failure to obtain informed consent; Severe disease conditions, including hepatic, renal, respiratory, cardiac, gastrointestinal, endocrinal, and immune systems; GIT disorders, including gastritis/peptic ulcer, diarrhea/constipation, and irritable bowel disease; Chromosomal disorders; Surgically-remediable epilepsy; Allergies or any other contraindication to ketone supplements; Inapplicable recording of seizures; Incompliance to anti-seizure medications and/or irregular follow-up; Ketosis (βHB > 2 mmol/L); Recent intake of exogenous ketones, ketogenic diet, or any dietary restrictions/modifications; Hypo-/hyperglycemia; Metabolic acidosis; Malnutrition/obesity; Limitations to oral feeding (e.g., severe gastroesophageal reflux); Inborn errors of metabolism.

ClinicalTrials.gov NCT05670847